QUMAS, a provider of Compliance Solutions to highly regulated companies, announced the launch of its Enterprise Compliance Solution for Microsoft SharePoint 2010 at the 46th Annual Drug Information Association (DIA) Conference. The solution addresses all aspects of compliance content and process management, from Clinical through Regulatory, and on to Sales & Marketing, IT and Legal.
QUMAS' domain knowledge will now be available on a SharePoint 2010 platform.
"We have been approached by a number of firms that intend to make SharePoint 2010 a cornerstone of their technology infrastructure," said Kevin O'Leary, CEO QUMAS. " We recognize the game changing impact that SharePoint is having on the technology landscape. This is the single most exciting initiative we have undertaken in our 16 years of business and we are delighted to be working with Microsoft to deliver a compliance solution built entirely on the SharePoint 2010 platform."
The QUMAS Compliance Solution adds key solution-specific functionality that leverages and extends the underlying SharePoint platform to support industry demands in a number of key areas. These will include:
-Manufacturing Controlled Documents
-CAPA's and Deviations
-Clinical Trial Management
-Regulatory Documentation
-SOP Management (Policies and Procedures)
-Customer Complaints
-Change Control
-Policy Training and Certification
-R&D Document Control
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
2 Commerce Drive
Cranbury, NJ 08512